Sanofi and Kaken to Terminate their Co-Marketing Agreement for Clexane by the Year End 2019

 Sanofi and Kaken to Terminate their Co-Marketing Agreement for Clexane by the Year End 2019

Sanofi and Kaken to Terminate their Co-Marketing Agreement for Clexane by the Year End 2019

Shots:

  • In accordance with the expiration of the effective period of the co-marketing agreement, the companies will terminate their co-marketing agreement for Clexane SC Kit 2000 IU on Dec 31, 2019
  • In Jan’2008, Sanofi got manufacturing and marketing approval for Clexane SC Kit 2000 IU while Kaken initiated marketing and information service activities in Jul’2010 under the co-marketing agreement between the two companies
  • Clexane is an anticoagulant therapy indicated to prevent venous thromboembolism. From Jan 01, 2020 Sanofi will start marketing and information service activities for Clexane on its own

Click here to­ read full press release/ article | Ref: Kaken | Image: Amcham

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post